Schisanwilsonin I exhibits significant anti-inflammatory and neuroprotective properties, making it a compound of interest in the development of treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. It has been shown to inhibit key inflammatory pathways in the central nervous system, particularly by suppressing the activation of microglial cells and reducing the production of pro-inflammatory cytokines like TNF-α and IL-6. Additionally, Schisanwilsonin I demonstrates antioxidant activity, helping to mitigate oxidative stress in neuronal tissues. These combined effects suggest its potential use in therapeutic strategies aimed at slowing disease progression and preserving cognitive function. Research is also exploring its role in liver protection, where it may help reduce hepatotoxicity and support liver regeneration through modulation of detoxification enzymes.